Key Highlights
- Entact Bio appoints Ruben Tommasi, Ph.D., as Chief Scientific Officer.
- Dr. Tommasi brings 30 years of drug discovery leadership across multiple therapeutic areas.
- Tommasi previously served at Dunad Therapeutics and Entasis Therapeutics, driving successful clinical outcomes.
- Entact Bio focuses on precision medicines that enhance beneficial protein function via the Encompass™ platform.
Source: Business Wire
Notable Quotes
- “We’re thrilled to welcome Ruben, who brings deep expertise in drug discovery and has a proven record in successfully advancing compounds from program inception to clinical development and regulatory approval.” — Victoria Richon, Ph.D., CEO at Entact Bio
- “I was very attracted to the innovative modality Entact is developing as it holds tremendous potential to pursue new, undrugged targets believed to be beneficial against disease.” — Ruben Tommasi, Ph.D., Chief Scientific Officer at Entact Bio
SoHC's Take
The appointment of Dr. Ruben Tommasi as Chief Scientific Officer marks a pivotal moment for Entact Bio. His extensive experience in drug discovery, particularly in progressing compounds through to FDA approval, will likely accelerate the development of Entact’s innovative ENTAC™ medicines. With a proven track record across multiple therapeutic areas, Dr. Tommasi’s leadership will strengthen the company’s ability to explore novel therapeutic targets and address diseases that current treatments cannot effectively reach. This strategic move positions Entact Bio to further expand its impact on precision medicine, potentially offering new hope to patients in underserved disease areas.
Heading
Key Highlights Ginkgo Bioworks releases first proprietary protein LLM, trained on exclusive datasets.Collaboration with Google Cloud enables AI-driven drug discovery tools.Open API allows researchers to access Ginkgo’s machine ...
Key Highlights Courtney Green joins QGenda as Vice President of Nurse and Staff Solutions.Brings over 20 years of clinical and operational leadership experience.Focus on optimizing ...
Key Highlights Vyne Medical® acquires Extract Systems®, a leader in data extraction solutions.Accelerates healthcare automation by integrating AI and machine learning ...
Key Highlights PatientPay integrates with Azalea Health’s API to streamline patient billing for ambulatory providers.Faster revenue capture with less than 14 days to payment, ...
Key Highlights Partnership streamlines revenue cycle management for ABA therapy providers.Flychain’s financial tools offer real-time insights, secure funding, and automation.Raven ...
Key Highlights Nura Bio closes $140M Series A financing to support clinical development.Shilpa Sambashivan, Ph.D., appointed as CEO following Phase 1 success ...
